Recent Publications

  1. Taylor R, Jr., Raffa RB, Pergolizzi JV, Jr. Controlled release formulation of oxycodone in patients with moderate to severe chronic osteoarthritis: a critical review of the literature. J Pain Res. 2012;5:77-87.
  2. Taylor R, Jr., Lemtouni S, Weiss K, Pergolizzi JV, Jr. Pain Management in the Elderly: An FDA Safe Use Initiative Expert Panel's View on Preventable Harm Associated with NSAID Therapy. Curr Gerontol Geriatr Res. 2012;2012:196159.
  3. Raffa RB, Tallarida RJ, Taylor R, Jr., Pergolizzi JV, Jr. Fixed-dose combinations for emerging treatment of pain. Expert Opin Pharmacother. Jun 2012;13(9):1261-1270.
  4. Pergolizzi JV, Jr., Raffa RB, Taylor R, Jr., Rodriguez G, Nalamachu S, Langley P. A Review of Duloxetine 60 mg Once-Daily Dosing for the Management of Diabetic Peripheral Neuropathic Pain, Fibromyalgia, and Chronic Musculoskeletal Pain Due to Chronic Osteoarthritis Pain and Low Back Pain. Pain Pract. Jun 21 2012.
  5. Pergolizzi JV, Jr., Raffa RB, Tallarida R, Taylor R, Labhsetwar SA. Continuous multimechanistic postoperative analgesia: a rationale for transitioning from intravenous acetaminophen and opioids to oral formulations. Pain Pract. Feb 2012;12(2):159-173.
  6. Pergolizzi JV, Raffa RB, Pergolizzzi JS, Taylor R. Non-Analgesic Effects of Opioids: Factors Relevant to Opioid Abuse and Abuse-Deterrent Formulations. Curr Pharm Des. Jun 28 2012.
  7. Pergolizzi JV, Jr., Philip BK, Leslie JB, Taylor R, Jr., Raffa RB. Perspectives on transdermal scopolamine for the treatment of postoperative nausea and vomiting. J Clin Anesth. Jun 2012;24(4):334-345.
  8. Pergolizzi JV, Jr., Gharibo C, Passik S, et al. Dynamic risk factors in the misuse of opioid analgesics. J Psychosom Res. Jun 2012;72(6):443-451.
  9. Angeletti C, Guetti C, Papola R, et al. Pain after earthquake. Scand J Trauma Resusc Emerg Med. Jun 29 2012;20(1):43.
  10. Pergolizzi JV, Jr., Taylor R, Jr., Raffa RB. Extended-release formulations of tramadol in the treatment of chronic pain. Expert Opin Pharmacother. Aug 2011;12(11):1757-1768.
  11. Pergolizzi JV, Jr., Gan TJ, Plavin S, Labhsetwar S, Taylor R. Perspectives on the role of fospropofol in the monitored anesthesia care setting. Anesthesiol Res Pract. 2011;2011:458920.
  12. Raffa RB, Pergolizzi JV Jr. Is Morphine Medicine's Biggest Misnomer? (July/August). Ann Pharmacother. 2012 Jul 3. [Epub ahead of print]
  13. Angeletti C, Guetti C, Papola R, Petrucci E, Ursini ML, Ciccozzi A, Masi F, Russo MR, Squarcione S, Paladini A, Pergolizzi J, Taylor R Jr, Varrassi G, Marinangeli F. Pain after earthquake. Scand J Trauma Resusc Emerg Med. 2012 Jun 29; 20(1):43. [Epub ahead of print]
  14. Pergolizzi JV, Raffa RB, Pergolizzi JS, Taylor R. Non-Analgesic Effects of Opioids: Factors Relevant to Opioid Abuse and Abuse-Deterrent Formulations. Curr Pharm Des. 2012 Jun 28. [Epub ahead of print]
  15. Pergolizzi JV Jr, Raffa RB, Taylor R Jr, Rodriguez G, Nalamachu S, Langley P. A Review of Duloxetine 60 mg Once-Daily Dosing for the Management of Diabetic Peripheral Neuropathic Pain, Fibromyalgia, and Chronic Musculoskeletal Pain Due to Chronic Osteoarthritis Pain and Low Back Pain. Pain Pract. 2012 Jun 21. Doi: 10.1111/j.1533-2500.2012.00578.x. [Epub ahead of print]
  16. Pergolizzi JV Jr, Gharibo C, Passik S, Labhsetwar S, Taylor R Jr, Pergolizzi JS, Müller-Schwefe G. Dynamic risk factors in the misuse of opioid analgesics. J Psychosom Res. 2012 Jun; 72(6):443-51. Epub 2012 Apr 5
  17. Pergolizzi JV Jr, Philip BK, Leslie JB, Taylor R Jr, Raffa RB. Perspectives on transdermal scopolamine for the treatment of postoperative nausea and vomiting. J Clin Anesth. 2012 Jun; 24(4):334-45.
  18. Daitch J, Frey ME, Silver D, Mitnick C, Daitch D, Pergolizzi J. Conversion of chronic pain patients from full-opioid agonists to sublingual buprenorphine. Pain Physician. 2012 Jul; 15(3 Suppl):ES59-66.
  19. Pergolizzi, Van de Laar M, Langford R, Mellinghoff HU, Merchante IM, Nalamachu S, O’Brien J, Perrot S, and Raffa RB. Tramadol/paracetamol fixed-dose combination in the treatment of moderate to severe pain Journal of Pain Research 2012:5 327–346
  20. Angeletti C, Guetti C, Papola R, Petrucci E, Ursini ML, Ciccozzi A, Masi F, Russo MR, Squarcione S, Paladini A, Pergolizzi J, Taylor R Jr, Varrassi G, Marinangeli F. Pain after earthquake. Scand J Trauma Resusc Emerg Med. 2012 Jun 29; 20:43
  21. Taylor R Jr, Pergolizzi JV, Sinclair A, Raffa RB, Aldington D, Plavin S, Apfel CC. Transversus Abdominis Block: Clinical Uses, Side Effects, and Future Perspectives. Pain Pract. 2012 Sep 12. Doi: 10.1111/j.1533-2500.2012.00595.x. [Epub ahead of print]
  22. Raffa RB, Pergolizzi JV, Muniz E, Taylor R, and Pergolizzi J. Designing Opioids That Deter Abuse Pain Research and Treatment 2012, Article ID 282981, 10 pages doi:10.1155/2012/282981
  23. Yarlas A, Miller K, Wen W, Dain B, Lynch SY, Pergolizzi J, Raffa R, Ripa S. A Randomized, Placebo-Controlled Study of the Impact of the 7-Day Buprenorphine Transdermal System on Health-Related Quality of Life in Opioid-Naïve Patients with Moderate-to-Severe Chronic Low Back Pain. The Journal of Pain, Vol 13 No (1), 2013: pp 14-23.
  24. Pergolizzi J, Taylor R, Plancarte R, Muniz E. Es la Buprenorfina una buena opción en el manejo de dolor postoperatorio? Rev Soc Esp Dolor 2012; 19(6): X-X
  25. Pergolizzi, JV. Treatment of Chronic Pain in Older People: Evidence-Based Choice of Strong-Acting Opioids. Drugs Aging. 2012:12 (29): 993-95.
  26. Pergolizzi JV Jr, Labhsetwar S, Lequang JA. Compounding Pharmacies: Who is in Charge? Pain Pract. 2013 Jan 28. Doi: 10.1111/papr.12033. [Epub ahead of print]
  27. Taylor R, Pergolizzi JV, Raffa RB. Tapentadol extended release for chronic pain patients. Adv Ther. 2013 Jan; 30(1):14-27. Doi: 10.1007/s12325-013-0002-y. Epub 2013 Jan 15.
  28. van Laar M, Pergolizzi JV Jr, Mellinghoff HU, Merchante IM, Nalamachu S, O'Brien J, Perrot S, Raffa RB Pain treatment in arthritis-related pain: beyond NSAIDs. Open Rheumatol J. 2012; 6:320-30. Doi: 10.2174/1874312901206010320. Epub 2012 Dec 13.
  29. Pergolizzi JV, Raffa RB, Taylor R, Nagar S, Labhsetwar S, Sinclair N, Gould EM. An open-label pharmacokinetic study of oxymorphone extended release in the presence of naltrexone in the older adult. J Opioid Manag. 2012 Nov-Dec; 8(6):383-93. Doi: 10.5055/jom.2012.0138
  30. Obrien J, Pergolizzi J, van de Laar M, Mellinghoff HU, Moron Merchante I, Nalamachu S, Perrot S, Raffa RB. Fixed-dose combinations at the front line of multimodal pain management: perspective of the nurse-prescriber. Nursing: Research and Reviews 2013:3
  31. Apfel CC, Turan A, Souza K, Pergolizzi J, Hornuss C Intravenous acetaminophen reduces postoperative nausea and vomiting: a systematic review and meta-analysis. Pain. 2013 Jan 11. pii: S0304-3959(13)00009-2. Doi: 10.1016/j.pain.2012.12.025. [Epub ahead of print]
  32. Taylor R, Pergolizzi J, Porreca F, Raffa R. Opioid antagonists for pain. Expert. Opin. Investig. Drugs (2013) 22(4).
  33. Merchante I, Pergolizzi J, van de Laar M, Mellinghoff HU, Nalamachu S, O’Brien J, Perrot S, and Raffa RB. Tramadol/Paracetamol Fixed-Dose Combination for Chronic Pain Management in Family Practice: A Clinical Review. ISRN Family Medicine, vol. 2013, Article ID 638469, 15 pages, 2013. doi:10.5402/2013/638469.
  34. Leslie JB, Raffa RB, Taylor R, Muniz E, Nalamachu S, Pergolizzi JV. Essential Oxygen Oil for Treatment of Sport-Related Injuries American Journal of Sports Science and Medicine, 2013, Vol. 1, No. 1, 7-12
  35. Pergolizzi JV. Treatment of chronic pain in older people: evidence-based choice of strong-acting opioids. Drugs Aging. 2012 Dec; 29(12):993-5; author reply 997-8. Doi: 10.1007/s40266-012-0025-0
  36. Pergolizzi J, Ben Joseph R, Chang CL, Pierz K, Shah D, Hess G Impact of dosage strength on medication persistence among patients treated with buprenorphine transdermal system. Value Health. 2013 May; 16(3):A120. Doi: 10.1016/j.jval.2013.03.576. Epub 2013 May 3.
  37. Pergolizzi J, Hess G, Chang CL, Shah D, Pierz K, Benjoseph R Factors predicting medication persistence among patients initiating Buprenorphine transdermal system. Value Health. 2013 May; 16(3):A120. Doi: 10.1016/j.jval.2013.03.575. Epub 2013 May 3.
  38. Vadivelu N, Gowda AM, Urman RD, Jolly S, Kodumudi V, Maria M, Taylor R Jr, Pergolizzi J. Ketorolac tromethamine - routes and clinical implications. Pain Pract. 2015 Feb; 15(2):175-93. Doi: 10.1111/papr.12198. Epub 2014 Apr 16.
  39. Pergolizzi JV Jr, Ben-Joseph R, Chang CL, Hess G. US practitioner prescribing practices and patient characteristics of those newly treated with a buprenorphine transdermal patch system. Curr Med Res Opin. 2014 Aug; 30(8):1579-87. Doi: 10.1185/03007995.2014.901941. Epub 2014 Apr 4.
  40. Summers K, Pergolizzi J, Ma L, Foster D, Overholser B, Sowinski K. The prevalence of opioid-related major potential drug-drug interactions and their impact on health care costs. Value Health. 2013 May; 16(3):A12. Doi: 10.1016/j.jval.2013.03.076. Epub 2013 May 3.
  41. Pergolizzi JV Jr, Ma L, Foster DR, Overholser BR, Sowinski KM, Taylor R Jr, Summers KH . The prevalence of opioid-related major potential drug-drug interactions and their impact on health care costs in chronic pain patients. J Manag Care Spec Pharm. 2014 May; 20(5):467-76.
  42. Angeletti C, Guetti C, Ursini ML, Taylor R Jr, Papola R, Petrucci E, Ciccozzi A, Paladini A, Marinangeli F, Pergolizzi J, Varrassi G. Low Back Pain in a Natural Disaster. Pain Pract. 2013 Jun 14. Doi: 10.1111/papr.12087. [Epub ahead of print]
  43. Pergolizzi J, Ahlbeck K, Aldington D, Alon E, Coluzzi F, Dahan A, Huygen F, Kocot-Kępska M, Mangas AC, Mavrocordatos P, Morlion B, Müller-Schwefe G,Nicolaou A, Pérez Hernández C, Sichère P, Schäfer M, Varrassi G. The development of chronic pain: physiological CHANGE necessitates a multidisciplinary approach to treatment. Curr Med Res Opin 2013 Jul 3. [Epub ahead of print]
  44. Pergolizzi JV Jr, Lequang JA. Abuse-Deterrent Formulations of Opioid Analgesics. Pain Pract. 2013 Aug 6. Doi: 10.1111/papr.12093
  45. Raffa RB, Pergolizzi JV Jr. Opioid-induced hyperalgesia: is it clinically relevant for the treatment of pain patients? Pain Manag Nurs. 2013 Sep; 14(3):e67-83.
  46. Raffa RB, Taylor R Jr, Pergolizzi JV Jr Sequestered naltrexone in sustained release morphine or oxycodone - a way to inhibit illicit use? Expert Opin Drug Saf. 2013 Nov 11. [Epub ahead of print]
  47. Pergolizzi JV Jr, Taylor R Jr, Nalamachu S, Raffa RB, Carlson DR, Varanasi RK, Kopecky EA Challenges of treating patients with chronic pain with dysphagia (CPD): physician and patient perspectives. Curr Med Res Opin. 2013 Oct 28. [Epub ahead of print]
  48. Pergolizzi JV Jr, Taylor R Jr, Raffa RB, Nalamachu S, Chopra M. Fast-Acting Sublingual Zolpidem for Middle-of-the-Night Wakefulness. Sleep Disord. 2014; 2014:527109. Doi: 10.1155/2014/527109. Epub 2014 Feb 5. Review.
  49. Taylor R Jr, Pergolizzi JV, Raffa RB, Nalamachu S, Balestrieri PJ. Pain and obesity in the older adult. Curr Pharm Des. 2014; 20(38):6037-41.
  50. Pergolizzi JV Jr, Raffa RB, Taylor R Jr. Treating acute pain in light of the chronification of pain. Pain Manag Nurs. 2014 Mar; 15(1):380-90. Doi: 10.1016/j.pmn.2012.07.004. Epub 2012 Aug 25. Review.
  51. Pergolizzi JV, Pappagallo M, LeQuang J, Labhsetwar S, Taylor R. New health care measures: emphasis on better management of postsurgical pain and postoperative nausea and vomiting. Hosp Pract (1995). 2014 Feb; 42(1):65-74. Doi: 10.3810/hp.2014.02.1093.
  52. Miller K, Yarlas A, Wen W, Dain B, Lynch SY, Ripa SR, Pergolizzi JV Jr, Raffa R. The impact of buprenorphine transdermal delivery system on activities of daily living among patients with chronic low back pain: an application of the international classification of functioning, disability and health. Clin J Pain. 2014 Dec; 30(12):1015-22. Doi: 10.1097/AJP.0000000000000068.
  53. Raffa RB, Pergolizzi JV Jr. A modern analgesics pain 'pyramid'. J Clin Pharm Ther. 2014 Feb; 39(1):4-6. Doi: 10.1111/jcpt.12110. Epub 2013 Nov 19.
  54. Morley-Forster PK, Pergolizzi JV, Taylor R Jr, Axford-Gatley RA, Sellers EM. Mitigating the risk of opioid abuse through a balanced undergraduate pain medicine curriculum. J Pain Res. 2013 Dec 4; 6:791-801. Doi: 10.2147/JPR.S47192. Review.
  55. Antor MA, Uribe AA, Erminy-Falcon N, Werner JG, Candiotti KA, Pergolizzi JV and Bergese SD (2014) The effect of transdermal scopolamine for the prevention of postoperative nausea and vomiting. Front. Pharmacol. 5:55. doi: 10.3389/fphar.2014.00055
  56. Nalamachu SR, Pergolizzi J, Taylor R Jr, Slatkin NE, Barrett AC, Yu J, Bortey E, Paterson C, Forbes WP. Efficacy and Tolerability of Subcutaneous Methylnaltrexone in Patients with Advanced Illness and Opioid-Induced Constipation: A Responder Analysis of 2 Randomized, Placebo-Controlled Trials. Pain Pract. 2014 May 10. doi: 10.1111/papr.12218. [Epub ahead of print]
  57. Müller-Schwefe G, Ahlbeck K, Aldington D, Alon E, Coaccioli S, Coluzzi F, Huygen F, Jaksch W, Kalso E, Kocot-Kępska M, Kress HG, Mangas AC, Ferri CM, Morlion B, Nicolaou A, Hernández CP, Pergolizzi J, Schäfer M, and Sichère P. Pain in the cancer patient: different pain characteristics CHANGE pharmacological treatment requirements. Curr Med Res Opin. 2014 Sep; 30(9):1895-908. doi: 10.1185/03007995.2014.925439. Epub 2014 Jun 10.
  58. Nalamachu S, Pergolizzi JV, Raffa RB, Lakkireddy DR, Taylor R Jr. Drug-drug interaction between NSAIDS and low-dose aspirin: a focus on cardiovascular and GI toxicity. Expert Opin Drug Saf. 2014 Jul; 13(7):903-17. Doi: 10.1517/14740338.2014.924924. Epub 2014 Jun 6. Review.
  59. Galia E, Williams Y, Van Hove B, Pergolizzi J, Etropolski M, Vorsanger G. Evaluation of the tamper-resistant properties of tapentadol extended-release tablets: results of in vitro laboratory analyses. J Opioid Manag. 2014 May-Jun; 10(3):149-58. Doi: 10.5055/jom.2014.0203.
  60. Raffa RB, Gudin JA, Nalamachu S, Pergolizzi JV Jr. 'Selective' COX-1 or COX-2 NSAIDs: time to change a misleading measure. J Clin Pharm Ther. 2014 Oct; 39(5):455-6. Doi: 10.1111/jcpt.12192. Epub 2014 Jul 29.
  61. Raffa RB, Haidery M, Huang HM, Kalladeen K, Lockstein DE, Ono H, Shope MJ, Sowunmi OA, Tran JK, Pergolizzi JV Jr. The clinical analgesic efficacy of buprenorphine. J Clin Pharm Ther. 2014 Dec; 39(6):577-83. Doi: 10.1111/jcpt.12196. Epub 2014 Jul 29.
  62. Taylor R, Raffa RB, Pergolizzi JV. Opioid formulations with sequestered naltrexone: a perspective review. Ther Adv Drug Saf. 2014 Jun; 5(3):129-37. doi: 10.1177/2042098614526769. Review.
  63. Radnovich R, Chapman CR, Gudin JA, Panchal SJ, Webster LR, Pergolizzi JV Jr. Acute pain: effective management requires comprehensive assessment. Postgrad Med. 2014 Jul; 126(4):59-72. doi: 10.3810/pgm.2014.07.2784.
  64. Smith HS, Raffa RB, Pergolizzi JV, Taylor R, Tallarida RJ. Combining opioid and adrenergic mechanisms for chronic pain. Postgrad Med. 2014 Jul; 126(4):98-114. Doi: 10.3810/pgm.2014.07.2788. Review.
  65. Ciccozzi A, Angeletti C, Guetti C, Pergolizzi J, Angeletti PM, Mariani R, Marinangeli F . Regional anesthesia techniques for carotid surgery: the state of art. J Ultrasound. 2014 May 1; 17(3):175-83. Doi: 10.1007/s40477-014-0094-5. eCollection 2014 Sep.
  66. Daitch D, Daitch J, Novinson D, Frey M, Mitnick C, Pergolizzi J Jr . Conversion from high-dose full-opioid agonists to sublingual buprenorphine reduces pain scores and improves quality of life for chronic pain patients. Pain Med. 2014 Dec; 15(12):2087-94. Doi: 10.1111/pme.12520. Epub 2014 Sep 12.
  67. Langley PC, Pergolizzi JV Jr, Taylor R Jr, Ridgway C. Antioxidant and associated capacities of camu camu (Myrciaria dubia): a systematic review. J Altern Complement Med. 2015 Jan; 21(1):8-14. Doi: 10.1089/acm.2014.0130. Epub 2014 Oct 2.
  68. Pergolizzi JV, Gharibo C, Ho KY . Treatment Considerations for Cancer Pain: A Global Perspective. Pain Pract. 2014 Dec 3. Doi: 10.1111/papr.12253. [Epub ahead of print]
  69. Yarlas A, Miller K, Wen W, Lynch SY, Munera C, Pergolizzi J, Raffa R, Ripa SR. Buprenorphine transdermal system compared with placebo reduces interference in functioning for chronic low back pain. Postgrad Med. 2015 Jan; 127(1):38-45. Epub 2014 Dec 15.
  70. Yarlas A, Miller K, Wen W, Lynch SY, Ripa SR, Pergolizzi J, Raffa RB. Buprenorphine Transdermal System Improves Sleep Quality and Reduces Sleep Disturbance in Patients with Moderate-to-Severe Chronic Low Back Pain: Results from Two Randomized Controlled Trials. Pain Pract. 2015 Jan 20. Doi: 10.1111/papr.12281. [Epub ahead of print]
  71. Pergolizzi JV, Köknel Talu G, Zmponga G, Erdine S, Taylor R, Ayan B, Raffa RB. Maximizing value in opioid utilization: Is oxycodone immediate release a good option for pain management? Agri. 2015 Jan; 27(1):1-11. Doi: 10.5505/agri.2015.79663.
  72. Vadivelu N, Gowda AM, Urman RD, Jolly S, Kodumudi V, Maria M, Taylor R Jr, Pergolizzi JV Jr. Ketorolac tromethamine - routes and clinical implications. Pain Pract. 2015 Feb;15(2):175-93. doi: 10.1111/papr.12198. Review.
  73. Pergolizzi JV, Ben-Joseph R, Chang CL, Hess G. Predicting medication persistence to buprenorphine transdermal system. Pain Pract. 2015 Feb;15(2):140-9. doi: 10.1111/papr.12155.
  74. Pergolizzi JV Jr. DEA reschedules hydrocodone combination products. Pain Pract. 2015 Feb; 15(2):95-7. Doi: 10.1111/papr.12268. No abstract available.
  75. Pergolizzi JV Jr, Zampogna G, Taylor R Jr, Raffa RB. Long-term efficacy, safety and tolerability of Remoxy for the management of chronic pain. Expert Rev Neurother. 2015 Mar; 15(3):231-8. Doi: 10.1586/14737175.2015.1015418. Epub 2015 Feb 15.
  76. Coluzzi F, Pergolizzi J, Raffa RB, Mattia C. The unsolved case of "bone-impairing analgesics": the endocrine effects of opioids on bone metabolism. Ther Clin Risk Manag. 2015 Mar 31; 11:515-23. Doi: 10.2147/TCRM.S79409. eCollection 2015.
  77. Pergolizzi JV Jr, Taylor R Jr, Raffa RB. Intranasal ketorolac as part of a multimodal approach to postoperative pain. Pain Pract. 2015 Apr; 15(4):378-88. Doi: 10.1111/papr.12239. Epub 2014 Aug 28.
  78. Yarlas A, Miller K, Wen W, Lynch SY, Munera C, Dain B, Pergolizzi JV Jr, Raffa R, Ripa SR. A Subgroup Analysis Found no Diminished Response to Buprenorphine Transdermal System Treatment for Chronic Low Back Pain Patients Classified with Depression. Pain Pract. 2015 Apr 11. Doi: 10.1111/papr.12298. [Epub ahead of print]
  79. Pergolizzi JV Jr, Taylor R Jr, Raffa RB. Intranasal ketorolac as part of a multimodal approach to postoperative pain. Pain Pract. 2015 Apr;15(4):378-88. doi: 10.1111/papr.12239. Review.
  80. Langley PC, Pergolizzi JV Jr, Taylor R Jr, Ridgway C. Antioxidant and associated capacities of Camu camu (Myrciaria dubia): a systematic review. J Altern Complement Med. 2015 Jan;21(1):8-14. doi: 10.1089/acm.2014.0130. Review.
  81. Vadivelu N, Gowda AM, Urman RD, Jolly S, Kodumudi V, Maria M, Taylor R Jr, Pergolizzi JV Jr. Ketorolac tromethamine - routes and clinical implications. Pain Pract. 2015 Feb;15(2):175-93. doi: 10.1111/papr.12198. Review.
  82. Pergolizzi JV, Ben-Joseph R, Chang CL, Hess G. Predicting medication persistence to buprenorphine transdermal system. Pain Pract. 2015 Feb;15(2):140-9. doi: 10.1111/papr.12155.
  83. Pergolizzi JV Jr, Taylor R Jr, Raffa RB. Intranasal ketorolac as part of a multimodal approach to postoperative pain. Pain Pract. 2015 Apr;15(4):378-88. doi: 10.1111/papr.12239. Review.
  84. Coluzzi F, Raffa RB, Pergolizzi J, Rocco A, Locarini P, Cenfra N, Cimino G, Mattia C. Tapentadol prolonged release for patients with multiple myeloma suffering from moderate-to-severe cancer pain due to bone disease. J Pain Res. 2015 May 8;8:229-38. doi: 10.2147/JPR.S83490.
  85. Eichenbaum G, Göhler K, Etropolski M, Steigerwald I, Pergolizzi J, Kim M, Vorsanger G. Does tapentadol affect sex hormone concentrations differently from morphine and oxycodone? An initial assessment and possible implications for opioid-induced androgen deficiency. J Opioid Manag. 2015 May-Jun;11(3):211-27. doi: 10.5055/jom.2015.0270.
  86. Pergolizzi JV Jr, Taylor R Jr, Raffa RB. The Potential Role of an Extended-Release, Abuse-Deterrent Oxycodone/Acetaminophen Fixed-Dose Combination Product for the Treatment of Acute Pain. Adv Ther. 2015 Jun;32(6):485-95. doi: 10.1007/s12325-015-0213-5.
  87. Pergolizzi JV Jr, Scholten W, Smith KJ, Leighton-Scott J, Willis JC, Henningfield JE. The unique role of transdermal buprenorphine in the global chronic pain epidemic. Acta Anaesthesiol Taiwan. 2015 Jun;53(2):71-6. doi: 10.1016/j.aat.2015.06.001.
  88. Nalamachu SR, Pergolizzi J, Taylor R Jr, Slatkin NE, Barrett AC, Yu J, Bortey E, Paterson C, Forbes WP. Efficacy and Tolerability of Subcutaneous Methylnaltrexone in Patients with Advanced Illness and Opioid-Induced Constipation: A Responder Analysis of 2 Randomized, Placebo-Controlled Trials. Pain Pract. 2015 Jul;15(6):564-71. doi: 10.1111/papr.12218.
  89. Pergolizzi JV Jr. New care measures and their impact on pain medicine: One pain specialist's perspective. Postgrad Med. 2015 Aug;127(6):616-22. doi: 10.1080/00325481.2015.1054616.
  90. Pergolizzi JV, Köknel Talu G, Zmponga G, Erdine S, Taylor R, Ayan B, Raffa RB. Maximizing value in opioid utilization: Is oxycodone immediate release a good option for pain management? Agri. 2015;27(1):1-11. doi: 10.5505/agri.2015.79663.
  91. Pergolizzi JV, Gharibo C, Ho KY. Treatment Considerations for Cancer Pain: A Global Perspective. Pain Pract. 2015 Nov;15(8):778-92. doi: 10.1111/papr.12253. Review.
  92. Coluzzi F, Mattia C, Savoia G, Clemenzi P, Melotti R, Raffa RB, Pergolizzi JV Jr. Postoperative Pain Surveys in Italy from 2006 and 2012: (POPSI and POPSI-2). Eur Rev Med Pharmacol Sci. 2015 Nov;19(22):4261-9.
  93. Meissner W, Coluzzi F, Fletcher D, Huygen F, Morlion B, Neugebauer E, Pérez AM, Pergolizzi J. Improving the management of post-operative acute pain: priorities for change. Curr Med Res Opin. 2015 Nov;31(11):2131-43. doi: 10.1185/03007995.2015.1092122.
  94. Nguyen V, Raffa RB, Taylor R, Pergolizzi JV Jr. The role of abuse-deterrent formulations in countering opioid misuse and abuse. J Clin Pharm Ther. 2015 Dec;40(6):629-34. doi: 10.1111/jcpt.12337. Review.
  95. Li Z, Pergolizzi JV, Huttner RP, Zampogna G, Breve F, Raffa RB. Management of opioid-induced constipation in pregnancy: a concise review with emphasis on the PAMORAs. J Clin Pharm Ther. 2015 Dec;40(6):615-9. doi: 10.1111/jcpt.12331. Review.
  96. Yarlas A, Miller K, Wen W, Lynch SY, Munera C, Dain B, Pergolizzi J, Raffa R, Ripa SR. Buprenorphine Transdermal System Improves Sleep Quality and Reduces Sleep Disturbance in Patients with Moderate-to-Severe Chronic Low Back Pain: Results from Two Randomized Controlled Trials. Pain Pract. 2016 Mar;16(3):345-58. doi: 10.1111/papr.12281.
  97. Pergolizzi J, Zampogna G, Taylor R, Gonima E, Posada J, Raffa RB. A Guide for Pain Management in Low and Middle Income Communities. Managing the Risk of Opioid Abuse in Patients with Cancer Pain. Front Pharmacol. 2016 Mar 1;7:42. doi: 10.3389/fphar.2016.00042. Review.
  98. Pergolizzi J, Raffa RB, Nalamachu S, Taylor R Jr. Evolution to low-dose NSAID therapy. Pain Manag. 2016 Apr;6(2):175-89. doi:10.2217/pmt.15.69.
  99. Coluzzi F, Taylor R Jr, Pergolizzi J Mattia C, Raffa RB, Braz J Good clinical practice guide for opioids in pain management: the three Ts - titration (trial), tweaking (tailoring), transition (tapering). Anesthesiol. 2016 May-Jun; 66 (3):310-7. doi: 10.1016/j.bjane.2014.09.005.
  100. Coluzzi F, Taylor R Jr, Pergolizzi J, Mattia C, Raffa RB. [Good clinical practice guide for opioids in pain management: the three Ts - titration (trial), tweaking (tailoring), transition (tapering).] Rev Bras Anestesiol. 2016 May-Jun; 66 (3):310-7. doi:10.1016/j.bjan.2016.02.008. Portuguese.
  101. Broglio K, Pergolizzi J, Kowalski M, Lynch SY, He E, Wen W. Efficacy and Safety of Once-Daily Extended-Release (ER) Hydrocodone in Individuals Previously Receiving ER Morphine for Chronic Pain. Pain Pract. 2016 Jun 18. doi: 10.1111/papr.12462. [Epub ahead of print]
  102. Broglio K, Pergolizzi J, Kowalski M, Lynch SY, He E, Wen W. Long-term effectiveness and safety of once-daily, single-entity, extended-release hydrocodone in patients of ≥75 years of age with moderate to severe nonmalignant and nonneuropathic pain. Geriatr Nurs. 2016 Aug 5. pii: S0197-4572(16)30102-1. doi: 10.1016/j.gerinurse.2016.07.004. [Epub ahead of print]
  103. Raffa RB, Taylor R Jr, Pergolizzi JV Jr, Nalamachu S, Edwards ES, Edwards ET. Application of human factors engineering (HFE) to the design of a naloxone auto-injector for the treatment of opioid emergencies. Drug Deliv Transl Res. 2016 Aug 25. [Epub ahead of print]
  104. Lin TC, Ger LP, Pergolizzi J, Raffa RB, Wang JO, Ho ST. Knowledge, Attitude and Practice Survey of Prescribing Opioids for Chronic Noncancer Pain in Taiwan-Comparison of Pain and Non-Pain Physicians. Pain Med. 2016 Aug 22. pii: pnw189. [Epub ahead of print]
  105. Pergolizzi J, Raffa RB, Zampogna G, Breve F, Colucci R, Schmidt WK, LeQuang JA. Comments and Suggestions from Pain Specialists Regarding the CDC's Proposed Opioid Guidelines. Pain Pract. 2016 Sep;16(7):794-808
  106. Pergolizzi JV Jr, Seow-Choen F, Wexner SD, Zampogna G, Raffa RB, Taylor R Jr. Perspectives on Intravenous Oxycodone for Control of Postoperative Pain. Pain Pract. 2016 Sep;16(7):924-34. doi: 10.1111/papr.12345. Review.
  107. Pergolizzi J, Paladini A, Varrassi G, Raffa RB. Change Pain: Ever Evolving-An Update for 2016. Pain Ther. 2016 Oct 14. [Epub ahead of print]
  108. Pergolizzi J, Raffa RB, LeQuang JA. The Centers for Disease Control and Prevention opioid guidelines: potential for unintended consequences and will they be abused? J Clin Pharm Ther. 2016 Dec; 41(6):592-593
  109. Lin TC, Ger LP, Pergolizzi Jr JV, Raffa RB, Wang JO, Ho ST. Knowledge, attitude and practice survey of prescribing opioids for chronic noncancer pain in Taiwan - Comparison of pain and non-pain physicians. Pain Medicine. First published online: 22 August 2016. DOI: http://dx.doi.org/10.1093/pm/pnw189.
  110. Pergolizzi JV, Raffa RB, Fleischer C, Zampogna G, Taylor R. Management of moderate to severe chronic low back pain with buprenorphine buccal film using novel bioerodible mucoadhesive technology. Journal of Pain Research. 2016;9:909-916. doi:10.2147/JPR.S87952.
  111. Lin Tso-Chou Ger Luo-Ping, Pergolizzi JV, Raffa RB, Ju-O Wang, Shung-Tai Ho. Knowledge, Attitude and Practice Survey of Prescribing Opioids for Chronic Noncancer Pain in Taiwan—Comparison of Pain and Non-Pain Physicians. Pain Medicine Aug 2016, pnw189; DOI: 10.1093/pm/pnw189